Animal parasiticides market accounted for over US$ 9.2 billion in 2019. It is anticipated to grow at a CAGR of ~7% from 2020 to 2030.
Companies are increasingly engaging in business development strategies, such as acquisitions, mergers, and agreements, to expand their animal parasiticides product portfolio. For instance, in August 2020, Merck Animal Health completed the acquisition of worldwide rights to VECOXAN (diclazuril) from Elanco Animal Health. It is an oral suspension and helps in the prevention of coccidiosis in calves and lambs. Similarly, companies are aiming at developing and launching new animal parasiticides products in the market. For instance, in February 2020, Norbrook Inc. launched Selarid (selamectin), a topical parasiticide for companion animals. It is a prescription treatment for protecting cats & dogs from heartworms, fleas, ear mites, and several other pests.
Major Key Players of the Animal Parasiticides Market are:
Intervet Inc. (Merck & Co. Inc.), Ceva, Zoetis, Boehringer Ingelheim International GmbH, Chanelle Pharma Group, Abbey Animal Health Pty Ltd, Bimeda, Inc., Norbrook, Vetoquinol S.A., Virbac, and Elanco among others.
No comments:
Post a Comment